Found 2,825 clinical trials

Q Q3 A3

PCSK9i in AAA1235

Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol

99 years and younger All Phase N/A

UPENN Case Test Trial 2 (Do Not Make Any Changes)

100 years and younger All Phase N/A

U Upenn Site User 7

UPENN Case Test Trial 4 (Do Not Make Any Changes)

100 years and younger All Phase N/A

U Upenn Site User 7

UPENN Case Test Trial 5 (Do Not Make Any Changes)

100 years and younger All Phase N/A

U Upenn Site User 6

UPENN Case Test Trial 7 (Do Not Make Any Changes)

100 years and younger All Phase N/A

U Upenn Site User 11

UPENN Case Test Trial 12 (Do Not Make Any Changes)

100 years and younger All Phase N/A

U UPENN Site User 1

UPENN Case Test Trial 13 (Do Not Make Any Changes)

100 years and younger All Phase N/A

A Alayna P. Tackett, PhD

change - Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

change - The main goal of this clinical trial is to learn about how safe the new drug TOP-N53 solution is when it is applied to open wounds on the fingertip (digital ulcers) in people with an uncommon illness that results in hard, thickened areas of skin and additional problems …

18-69 years All Phase 2

B Bin Xiong

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy combined with HIPEC is superior to only radical gastrectomy in terms of overall survival.

18-75 years All Phase 2

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary anti-tumor activity.

18 years and older All Phase 1